JW Asset Management’s Avadel Pharmaceuticals AVDL Stock Holding History

JW Asset Management’s Portfolio AVDL Stock Details AVDL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-444,439	Closed	-$1.85M	–	9
2019 Q3	$1.85M	Hold	444,439	–	–	1.63%	6
2019 Q2	$1.28M	Hold	444,439	–	–	0.69%	9
2019 Q1	$640K	Hold	444,439	–	–	0.33%	14
2018 Q4	$1.15M	Hold	444,439	–	–	0.84%	14
2018 Q3	$1.95M	Hold	444,439	–	–	1.05%	12
2018 Q2	$2.72M	Hold	444,439	–	–	1.74%	14
2018 Q1	$3.24M	Hold	444,439	–	–	3.19%	11
2017 Q4	$3.64M	Hold	444,439	–	–	3.88%	7
2017 Q3	$4.67M	Hold	444,439	–	–	3.42%	7
2017 Q2	$4.9M	Hold	444,439	–	–	3.12%	7
2017 Q1	$4.3M	Hold	444,439	–	–	0.9%	12
2016 Q4	$4.62M	Hold	444,439	–	–	3.07%	8
2016 Q3	$5.51M	Hold	444,439	–	–	3.79%	8
2016 Q2	$4.77M	Sell	444,439 -30,000	-6%	-$320K	3.79%	9
2016 Q1	$5.24M	Sell	474,439 -30,000	-6%	-$298K	3.42%	10
2015 Q4	$6.16M	Sell	504,439 -65,380	-11%	-$1.02M	2.3%	13
2015 Q3	$9.29M	Buy	569,819 +5,294	+0.9%	+$117K	3.37%	9
2015 Q2	$12M	Buy	564,525 +12,963	+2%	+$232K	3.64%	9
2015 Q1	$9.92M	Buy	551,562 +56,408	+11%	+$883K	4.29%	9
2014 Q4	$8.48M	Buy	+495,154	New	+$7.07M	6.37%	6

Other funds holding AVDL

BIP

Brandes Investment Partners La Jolla, California $14.3B AUM 23.11% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

BCM

Brown Capital Management Baltimore, Maryland $500M AUM 25.3% 1-Year Est. Return

ACP

Acuta Capital Partners Redwood City, California $143M AUM 773.18% 1-Year Est. Return

GJL

Gendell Jeffrey L $11.3B AUM 163.06% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

TCM

Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

JW Asset Management's AVDL Position: Q4 2019 in Review

JW Asset Management sold out of Avadel Pharmaceuticals (AVDL) in Q4 2019, closing a stake of 444,439 shares — an estimated $1.85M sold.

JW Asset Management first reported a position in AVDL in Q4 2014 and held it in 20 quarters. The position peaked at $12M in Q2 2015. 42 funds tracked by Wall St. Rank hold AVDL as of Q4 2019.

JW Asset Management reported no remaining Avadel Pharmaceuticals position as of Q4 2019 after selling out during the quarter.
JW Asset Management sold 444,439 Avadel Pharmaceuticals shares in Q4 2019, an estimated $1.85M.
JW Asset Management first reported a position in Avadel Pharmaceuticals in Q4 2014 and held it in 20 quarters.
JW Asset Management's Avadel Pharmaceuticals position peaked at $12M in Q2 2015.
42 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q4 2019.

Based on JW Asset Management's 13F filing for Q4 2019, filed 11 Feb 2020.